Evidence map›Paper›PMID 36092354›Full record

ArticleJournal of gastrointestinal oncology2022

Luteolin suppresses the growth of colon cancer cells by inhibiting the IL-6/STAT3 signaling pathway.

Jingwen Jiang, Fengting Zhu, Hui Zhang, Tao Sun, Fangfang Fu, Xuewu Chen, Yanhong Zhang

Open access · diamondAbstract read
In one paragraph

Article in Journal of gastrointestinal oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Frontiers in nutrition · 2025
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Application of Luteolin in Neoplasms and Nonneoplastic Diseases.International journal of molecular sciences · 2023
    Review
  17. Journal of gastrointestinal oncology · 2023
    Article
  18. Review
  19. Phytochemicals in Cancer Chemoprevention: Preclinical and Clinical Studies.Cancer control : journal of the Moffitt Cancer Center
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jingwen JiangDepartment of Medical Oncology, Hainan Province Hospital of Traditional Chinese Medicine, Haikou, China.
Fengting ZhuDepartment of Medical Oncology, Hainan Province Hospital of Traditional Chinese Medicine, Haikou, China.
Hui ZhangDepartment of Medical Oncology, Hainan Province Hospital of Traditional Chinese Medicine, Haikou, China.
Tao SunHainan Medical University, Haikou, China.
Fangfang FuDepartment of Medical Oncology, Hainan Province Hospital of Traditional Chinese Medicine, Haikou, China.
Xuewu ChenDepartment of Medical Oncology, Hainan Province Hospital of Traditional Chinese Medicine, Haikou, China.
Yanhong ZhangDepartment of Traditional Chinese Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Hainan Provincial Hospital of Traditional Chinese Medicine · CNHainan Medical University · CNSouth China University of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite the remarkable progression in colon cancer treatment in recent years, the pathological mechanism underlying this disease remains unclear. This study aimed to discuss the potential of luteolin in the treatment of colon cancer, from the perspective of traditional Chinese medicine, with a particular focus on the tumor microenvironment. Methods: Reverse transcription quantitative polymerase chain reaction and western blot were used to analyze the effects of luteolin on interleukin (IL)-6/signal transducer and activator of transcription 3 (STAT3)/Phospho-STAT3. Enzyme-linked immunosorbent assay was used to analyze the protein secretion of IL-6. Proliferation and transwell assays were used to analyze the growth and migration of luteolin and IL-6 in colon cancer cells, respectively. Results: Stimulation with lipopolysaccharides (LPS) promoted the M1 polarization of macrophages and increased the expression and secretion of IL-6. However, the presence of luteolin inhibited the effects of LPS. M1 polarization increased the proliferation rate, migration and invasion ability, and phosphorylation of STAT3 in colon cancer cells (SW620 and SW480). Luteolin inhibited these effects by reducing M1 polarization. To confirm that the action of luteolin is mediated by IL-6/STAT3 signaling, we treated SW620 and SW480 cells with recombinant IL-6 protein and anti-IL-6 antibody. IL-6 was observed to promote cell proliferation, enhance migration and invasion, and increase STAT3 phosphorylation. The opposite effect was observed with the anti-IL-6 antibody. In addition, IL-6 promoted LPS-induced M1 polarization, while the anti-IL-6 antibody enhanced the decrease in luteolin-induced M1 polarization. Conclusions: Luteolin suppressed the growth and migration/invasion potential of colon cancer cells by inhibiting the IL-6/STAT3 signaling pathway.

Indexed as

colon cancerInterleukin 6 (IL-6)lipopolysaccharide (LPS)luteolinsignal transducer and activator of transcription 3 (STAT3)

Identifiers

PMID36092354
PMCPMC9459197
OpenAlexW4290465726

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.